Checkpoint-Inhibitor Thyroiditis: A Side Effect That Isn't a Reason to Stop
A woman on immunotherapy for melanoma has developed a thyroid immune-related adverse event severe enough to alarm her oncology team. The disagreement is whether her symptoms cross the line into needing to pause the treatment that's controlling her cancer.
Beverly S., a 57-year-old retired travel agent, started pembrolizumab four months ago for stage III melanoma, with her most recent imaging showing no evidence of recurrence. Two weeks ago she developed a racing heartbeat, tremor, and heat intolerance intense enough that she went to urgent care on her own, worried something acute was wrong with her heart. Labs there showed a suppressed TSH and elevated free T4; a thyroid uptake scan obtained since showed diffusely low uptake, consistent with a destructive thyroiditis rather than new Graves' disease. She was started on propranolol for symptom control and referred back to her oncology team, who paused, uncertain whether continuing pembrolizumab through an active thyroid immune-related adverse event was safe.
Checkpoint-inhibitor thyroiditis behaves differently from most other immune-related adverse events these drugs cause, and that difference is the actual basis for the treatment decision, not a generic reassurance. Unlike colitis or hepatitis or hypophysitis, which can be severe enough to require high-dose steroids and holding immunotherapy, thyroid irAEs typically follow a self-limited course — a transient thyrotoxic phase from the initial destructive release, usually progressing to a permanent but entirely manageable hypothyroid phase, without the high-dose immunosuppression that would risk blunting the drug's own antitumor effect. Guidance for this specific irAE does not call for holding pembrolizumab in mild-to-moderate cases; the management is symptomatic and, later, hormonal, run in parallel with continued cancer treatment rather than as a reason to interrupt it. Where that guidance gets harder to apply cleanly is exactly her presentation: symptoms severe enough that she sought urgent, same-day care rather than calling her oncology office first, which is a genuinely more alarming initial presentation than the milder, incidentally-caught-on-routine-labs picture the "don't hold the drug" guidance is often illustrated with.
Deciding whether an alarming presentation changes the standard guidance
I'd continue pembrolizumab and manage this symptomatically, as the ASCO immune-related adverse event guideline, written by Brahmer and colleagues, recommends for checkpoint-inhibitor thyroiditis specifically. Her uptake scan confirms a destructive process, not new Graves' disease, and this specific irAE typically resolves into a manageable hypothyroid phase without needing steroids or a treatment hold — the mechanism here just doesn't behave like the severe irAEs that do require holding the drug.
I want to be careful about how much weight her presentation severity carries here. The standard guidance you're describing is usually illustrated with a milder, incidentally-caught case — hers was alarming enough that she went to urgent care worried about her heart, which is a meaningfully different starting picture than routine labs catching this quietly.
I'm not disputing the mechanism or the eventual course, but "this irAE type doesn't usually require holding the drug" was established largely from milder presentations, and applying that reassurance uniformly to a presentation this acute risks under-weighting how distressing and destabilizing this episode has actually been for her.
Her cardiac workup at urgent care was reassuring — a normal ECG and troponin argue against this being a cardiac event masquerading as thyroid symptoms, or a thyrotoxicosis severe enough to have caused real cardiac injury. That's useful, concrete information distinct from how frightening the episode felt to her: it tells us her presentation, while symptomatically severe, hasn't shown objective evidence of the kind of instability that would itself be a reason to hold immunotherapy, separate from what the general irAE-type guidance says.
Agreed: continue pembrolizumab unchanged, manage her symptoms with propranolol, and monitor for the expected transition into a hypothyroid phase requiring levothyroxine later.
Not agreed: whether her presentation severity should be documented as a distinct, more concerning subtype for future irAE guidance discussions, or treated as within the normal range of how this condition can present. The oncologist wants it flagged explicitly in her chart as an alarming presentation warranting closer-than-routine follow-up going forward; the endocrinologist views her course, now that objective testing is reassuring, as falling within ordinary variation for this irAE rather than a distinct, more severe category.